Prostatype Genomics AB - Asset Resilience Ratio
Prostatype Genomics AB (PROGEN) has an Asset Resilience Ratio of -10.72% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2023)
This chart shows how Prostatype Genomics AB's Asset Resilience Ratio has changed over time. Check Prostatype Genomics AB (PROGEN) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Prostatype Genomics AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PROGEN stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr-3.73 Million | -10.72% |
| Total Liquid Assets | Skr-3.73 Million | -10.72% |
Asset Resilience Insights
- Limited Liquidity: Prostatype Genomics AB maintains only -10.72% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Prostatype Genomics AB Industry Peers by Asset Resilience Ratio
Compare Prostatype Genomics AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ICON Public Limited Company
F:IJF |
Diagnostics & Research | 0.00% |
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 16.06% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Diagnósticos da América S.A
SA:DASA3 |
Diagnostics & Research | 10.42% |
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Cytogen Inc
KQ:217330 |
Diagnostics & Research | 32.97% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
Annual Asset Resilience Ratio for Prostatype Genomics AB (2021–2023)
The table below shows the annual Asset Resilience Ratio data for Prostatype Genomics AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 43.67% | Skr21.49 Million ≈ $2.31 Million |
Skr49.22 Million ≈ $5.30 Million |
+22.09pp |
| 2022-12-31 | 21.58% | Skr6.68 Million ≈ $718.66K |
Skr30.95 Million ≈ $3.33 Million |
-4.54pp |
| 2021-12-31 | 26.12% | Skr10.50 Million ≈ $1.13 Million |
Skr40.20 Million ≈ $4.33 Million |
-- |
About Prostatype Genomics AB
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doct… Read more